Pharmacology of apolipoprotein A-I

Curr Opin Lipidol. 1997 Aug;8(4):225-8. doi: 10.1097/00041433-199708000-00006.

Abstract

The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms. Depending upon the stage and type of atherosclerosis, different mechanisms may be more or less important. Knowledge of pharmacology of apolipoprotein A-I has strongly increased during past years and clinical studies have started with infusions of apolipoprotein A-I phospholipid complexes.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anticholesteremic Agents / pharmacology
  • Anticoagulants / pharmacology
  • Apolipoprotein A-I / pharmacology*
  • Arteriosclerosis / metabolism*
  • Biological Transport
  • Cholesterol / metabolism
  • Humans
  • Lipoproteins, HDL / metabolism*
  • Phospholipids / pharmacology*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Anticholesteremic Agents
  • Anticoagulants
  • Apolipoprotein A-I
  • Lipoproteins, HDL
  • Phospholipids
  • apolipoprotein A-I Milano
  • Cholesterol